Zylera Pharmaceuticals Announces Availability Of RELAMINE For The Treatment Of Osteoarthritis
1/25/2007 12:42:03 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Zylera Pharmaceuticals announced today that new RELAMINE™ (chondroitin 300mg, glucosamine 400mg and primorine™ 425mg), a novel, prescription treatment for osteoarthritis, is now available for patients throughout the U.S. RELAMINE is the first and only prescription product that contains pharmaceutical quality glucosamine, chondroitin and primorine. RELAMINE helps to reduce joint swelling and control pain while slowing the onset and progression of osteoarthritis.
comments powered by